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Background: Isoflavones are naturally occurring plant chemicals belonging to the “phytoestrogen” class. The aim of
the present study was to examine the effects of isoflavones obtained from Cordyceps sinensis (CSIF) on
development of estrogen deficiency-induced osteoporosis in ovariectomized rats.
Methods: After the rats were treated orally with CSIF, serum alkaline phosphatase (ALP), tartarate resistant acid
phosphatase (TRAP), serum osteocalcin (OC), homocysteine (HCY), C-terminal crosslinked telopeptides of collagen
type I (CTX), estradiol and interferonγ (IFN-γ) level were examined. At the same time, the urine calcium, plasma
calcium, plasma phosphorus and the mass of uterus, thymus and body were also examined.
Results: The beneficial effects of CSIF on improvement of osteoporosis in rats were attributable mainly to decrease
ALP activity, TRAP activity, CTX level and IFN-γ level. At the same time, CSIF also increase the OC and estradiol level
in ovariectomized osteopenic rats. The histological examination clearly showed that dietary CSIF can prevent bone
loss caused by estrogen deficiency.
Conclusion: The significant estrogenic activity of CSIF demonstrated that CSIF has significant estrogenic effects in
OVX rats.
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Cordyceps sinensis (CS) has been used as a tonic for
longevity, endurance, and vitality for thousands of years
by the Chinese [1]. Many studies have shown that CS
modulates immune responses [2-4], inhibits tumor cell
proliferation [5,6], enhances hepatic function [7], regu-
lates insulin sensitivity [8], decreases plasma cholesterol
levels [9], and has hypotensive and vasorelaxant activity
[10]. The effect of CS on osteoporosis had been studied
in our former paper [11]. However, the metabolites that
account for this effect have not been studies so far.
Many research groups have reported that isoflavones
were associated with human health benefits such as
decreased risks of various cancers, heart disease, cardiovas-
cular disease, and increased antioxidative effects [12-14].* Correspondence: GuangyueZfmmu@yeah.net
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unless otherwise stated.Isoflavones are naturally occurring plant chemicals belong-
ing to the “phytoestrogen” class [15]. These compounds
have structures similar to mammalian estrogens and
display both estrogenic and anti-estrogenic effects [16].
Epidemiological studies indicate that the significant
decrease in estrogen levels in women during the meno-
pausal period causes osteoporosis, a major public health
concern. Although hormone replacement therapy (HRT)
can help to prevent and treat the menopausal syn-
dromes, the side effects of HRT, such an increased risk
of developing breast and endometrial cancer, prevent the
acceptance of HRT [17,18]. Now, there is an interest in
using phytoestrogens to alleviate the menopausal symp-
toms, including development of osteoporosis. The aim
of the present study was to examine the effects of isofla-
vones obtained from CS on development of estrogen
deficiency-induced osteoporosis in ovariectomized rats.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Animals
Wistar rats (weighing 225 ± 25 g) were used in the study.
This study was performed in accordance with the Guide
for the Care and Use of Laboratory Animals. Care was
taken to minimize discomfort, distress, and pain to
the animals. The study was submitted to, and approved
by, the Fourth Military Medical University institutional
ethics committee.Isolation of CSIF
Cultured Cordyceps sinensis mycelium was obtained from
Shandong HandongLukang Pharmaceutical Co., Ltd.
(Shandong, China). The mycelium (100 g) was ground
and extracted with 80% methanol. The methanol solu-
tion was evaporated to dryness and suspended in high-
purity distilled water (500 mL) and then extracted using
ethyl acetate (500 mL × 3). The extracts appeared as
brown syrup (20 g) upon concentration. The sample was
then fractionated using silica gel column chromatography
in a stepwise gradient solvent system comprising 800 mL
each of the chloroform/methanol mixtures. Fraction 5 was
concentrated and loaded onto a Sephadex LH-20 column
in a solution that contained a methanol/distilled water
ratio of 8.5:1.5. Ten milliliter fractions were collected sepa-
rately, and the final purification of compound was accom-
plished via HPLC using an isocratic aqueous acetonitrile
solvent system. The CSIF was dissolved in CD3OD and
analysed by 1DNMR and 2D NMR techniques as reported
previously [19].Experimental design
The rats were randomly divided into five groups of animals,
four ovariectomized (OVX) and another was given a sham-
operation (control). Then group1 (sham) and 2 (OVX) were
treated orally with 10-ml of saline, group 3, group 4 and
group 5 were treated orally with CSIF (20 mg, 50 mg
and 100 mg )for 8 weeks respectively. Body weight of
the animals was recorded weekly.
On the last day of treatment urine was collected by
micturation induced by manual pressure from overnight
fasted animals and preserved at -20°C till further analysis
[20]. At necropsy, blood was collected from dorsal aorta
under ether anesthesia. After centrifugation, serum was
harvested and kept at -20°C until analysis. Uteri were
isolated. The absolute weight of uterine tissue was re-
corded and normalized with body weight (relative weight
of uterus, i.e., weight of uterus per 100 g of body weight)
of animals. The masses of thymus were also determined.
The femoral neck was processed for mechanical testing.
The left femur and L-4 vertebra bone were processed for
mineral content and histological analysis.Urine calcium (Ca) content measurement
Calcium content of urine was measured by flame photom-
etry (EHSY, China) after suitable dilution with double
distilled water [21].Serum calcium and phosphorus measurement
Serum samples were analyzed for their calcium and phos-
phorus contents by the arsenazo-3 dye and ammonium
molybdate colorimetric methods respectively.Serum hormone measurement
The serum was separated by centrifugation at 1000 × g for
10 min and then stored at -80°C until assay for E2, FSH,
and LH. Serum E2, FSH, and LH concentrations were
determined using radioimmunoassay (Sunbio, Inc., China).Plasma enzyme measurements
ALP and TRAP activity were determined by nitrophenol
based method as described by Bessy et al. [22] and Godkar
[23] respectively.Plasma proteins measurements
OCcontent was determined using an Osteocalcin EIA kit
(Xinqidi bio -Technology, Inc., China) as described in
the manufacturer’s directions. Two OC antibodies were
employed, each directed toward the N or C-terminal OC
molecule. HCY was measured by use of an enzymatic
fluorescence polarization immunoassay on an Axsym
analyzer (Abbott, Wiesbaden, Germany). CTX were
quantified by ELISA (Sunbio, Inc., China).Solubility studies
The procedure for the preparation of bone powder was
with the method described by Repo MA [24]. The min-
eral dissolution of bone powder was examined in acetate
buffered solutions [25]. Briefly, 10 mg aliquots of pow-
dered whole bone from rats were dispersed by sonic-
ation into 25 ml of 0.1 N acetate buffer pH = 5.0 at 37°C.
Portions of the supernatant media that were freed of
bone fragments by centrifugation for 2 minutes in an
Eppendorf microfuge were harvested every 5 minutes for
the first hour, hourly for the next 7 hours, and then at
24 hours. Calcium release from bone was followed by
measuring the calcium content of the supernatant sam-
ples by atomic absorption.Representative images of the uterine sections
The reproductive organs (uterine) were carefully removed,
cleaned, weighed and fixed in 10% formalin. Then it was
stained with Hematoxylin and Eosin (H&E) and examined
under light microscopy at 20× magnification.
Table 1 Effects of CSIF on the mass of uterus and thymus
in ovariectomized rats




Sham 270.11 ± 23.10** 340.15 ± 20.10** 125.11 ± 11.03**
OVX 540.1 ± 31.11 79.21 ± 3.21 29.7 ± 8.6
CSIF-100 288.3 ± 20.00** 309.10 ± 11.20** 115.6 ± 31.0*
CSIF-50 333.0 ± 20.22* 266.23 ± 11.11* 84.0 ± 9.2*
CSIF-20 530.0 ± 18.20 100.30 ± 22.22 51.6 ± 8.8
Relative weight of uterus is the weight of uterus normalized with body weight
(mg per 100 g of body weight). Values are mean ± SEM. n = 10. *P <0.05 vs.
OVX control; **P <0.01 vs. OVX control.
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The vertebrae were fixed in formaldehyde and then
sectioned and stained with H&E. The bone structure
was assessed under a light microscope.Data analysis
Group means were compared by Analysis of Variance
(ANOVA) with GraphPad Prism (GraphPad Software,
Inc.). Multiple comparison tests were performed with
Tukey for significant differences at P < 0.05.Results
Mass of uterus, thymus and body weights
Absolute and relative uterine weight was significantly
lower in OVX rats than in Sham rats. Significant in-
crease was observed with CSIF (p < 0.05, p < 0.01)
(Table 1). The OVX rats were shown by substantial in-
creases in the thymus mass in relation to the sham rats
(Table 1). CSIF significantly decreased the thymus mass
of the OVX rats (p < 0.05, p < 0.01). The body weights of
the rats are presented in Figure 1. Contrasted with the
other groups, the body weights of rats in CSIF treated
groups increased gradually 5 week later (p < 0.05 and
p < 0.01).Figure 1 Body weight changes for the study. (◆sham group, □OVX gro
and CSIF-50 significantly increased body weights compared to OVX animal
OVX group at the same timepoint.Urine calcium, serum calcium and serum phosphorus
content
In the present study significant increase in urinary Ca
excretion was observed in OVX control (Table 2). On
the contrary, CSIF significantly decreased urinary Ca
excretion (p < 0.01 and p < 0.05). The effects of treatment
with CSIF on plasma total calcium and inorganic phos-
phate concentrations are shown in Table 2. All of treat-
ments significantly decreased plasma total calcium and
inorganic phosphate concentrations.
Serum hormone measurement
Table 3 serum E2, FSH, and LH levels. The E2 levels of
the OVX group were significantly decreased compared
with those of the Sham group (P < 0.01). In contrast, the
serum FSH and LH levels of the OVX group were
significantly increased compared with those of the Sham
group (P < 0.01). CSIF treatment restored serum E2,
FSH, and LH to the same levels as in the Sham group.
Plasma enzyme measurements
In the present study significant increase in ALP and
TRAP levels were observed in OVX control (Table 4).
On the contrary, CSIF significantly decreased ALP and
TRAP levels (p < 0.01).
Plasma proteins measurements
The effects of treatment with CSIF on OC level was
shown in Table 5. All of treatments increased OC level.
However, the values of CSIF-100 treated group were
significantly higher than those of other treated group.
Compared with OVX control, there were no significant
differences in the increase of HCY content in CSIF groups
(Table 5). The serum levels of CTX were significantly
higher in the OVX group than in the other groups. The
values of CTX-100 treated group were significantly higher
than those of other groups (Table 5). The level of IFN-γ
was significantly higher in the OVX group than that in theup, ■CSIF-50group,▲CSIF-100 group and is ■CSIF-20 group ). CSIF-100
s, Values are mean ± SEM. n = 10. *p < 0.05, ** p < 0.01compared to the
Table 2 Effect of CSIF on serum calcium (Ca), inorganic










Sham group 48.61 ± 4.50** 8.00 ± 1.0* 5.10 ± 0.5 **
OVX group 110.55 ± 12.2 15.93 ± 1.3 10.10 ± 0.4
CSIF-100 50.22 ± 8.55** 10.01 ± 0.4* 6.20 ± 0.2**
CSIF-50 71.22 ± 10.0* 11.10 ± 0.5* 7.99 ± 0.6*
CSIF-20 99.62 ± 12.1 13.88 ± 0 .4 8.88 ± 0.5
*P <0.05 vs. OVX control; **P <0.01 vs. OVX control. (Mean ± standard
deviation) (n = 10).
Table 4 Effects of CSIF on plasma enzymes in
ovariectomized rats
Groups TRAP level (uM) ALP level (mM)
Sham 0.22 ± 0.11** 3.25 ± 0.12**
OVX 0.82 ± 0.11 7.21 ± 0.10
CSIF-100 0.46 ± 0.03** 4.00 ± 0.03*
CSIF-50 0.55 ± 0.02 5.33 ± 0.06*
CSIF-20 0.75 ± 0.03 6.30 ± 0.02
Values are mean ± SEM. n = 10. *P <0.05 vs. OVX control; **P <0.01 vs.
OVX control.
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rats decreased significantly the IFN-γ level (P < 0.05)
(Table 5).Solubility studies
As shown in Figure 2, mineral dissolution of bone from
the CSIF treated rats were reduced as compared with
the OVX group over the entire time period measured.
The differences between them and OVX group in the
rate of dissolution as well as the amount of calcium
released at 24 hours were highly significant (P < 0.01).Effects of CSIF on the uterine sections
Under light microscopy, we observed marked atrophy of
the rat uterus to about half its former size once the rats
are ovariectomised (OVX group). The size increased to
near normal in CSIF-treated rats (Figure 3C). Likewise
the endometrial thickness showed atrophy in the OVX
group (Figure 3B). After 8 weeks administration of CSIF
at all doses caused a reversal of the vaginal atrophy. This
effect was accompanied by mild hyperplasia of vaginal
epithelium. Cytoplasmic vacuolization of vaginal epithe-
lium was noted in rats on high dose of 100 mg CSIF
(Figure 3C). The general histological features of the squa-
mous epithelium of the vagina of the CSIF100-treated rats
closely resembled to that in SHAM rats (Figure 3A).Table 3 Effect of CSIF on serum E2, FSH, and LH levels in
ovariectomized rats
Different groups E2 ((pg/mL)) FSH (mIU/mL) LH (mIU/mL)
Sham group 28.4 ± 2.00** 1.80 ± 1.0* 1.10 ± 0.5 **
OVX group 12.5 ± 2.20 4.30 ± 1.0 3.10 ± 0.4
CSIF-100 20.22 ± 2.50** 2.01 ± 0.4* 1.20 ± 0.2**
CSIF-50 16.00 ± 5.50* 3.10 ± 0.5* 1.99 ± 0.6*
CSIF-20 14.22 ± 2.10 3.88 ± 0 .4 2.80 ± 0.5
*P <0.05 vs. OVX control; **P <0.01 vs. OVX control. (Mean ± standard
deviation) (n = 10).Effects of CSIF on bone structure changes
A sample photomicrograph is presented in Figure 4; it is
quite clear that trabecular bone loss is much higher in
the vertebrae of rat with OVX (Figure 4B), whereas the
vertebrae of CSIF100-fed OVX rat appear to be near
normal (Figure 4C).
Discussion
Phytoestrogens are a diverse class of non-steroidal com-
pounds that have an affinity for estrogen receptors α
and β for the peroxisome proliferator-activated receptor
(PPAR) family and for the aryl hydrocarbon receptor
[26-28]. Many phytoestrogens counteract the cellular
derailments that are responsible for the development of
metabolic syndrome [29-31]. Here we propose the effects
of isoflavones, which are naturally occurring plant chemi-
cals belonging to the “phytoestrogen” class, obtained from
Cordyceps sinensis on development of estrogen deficiency-
induced osteoporosis in ovariectomized rats.
According to ancient descriptions, Cordyceps sinensis
possesses important pharmacological activities for protect-
ing lung and kidney functions and in nourishing essential
and vital energy [32]. Body weight is a general index of the
health of an animal. The increases in body weight by CSIF
may contribute to maintaining the elevated periosteal bone
formation and inhibit endosteal bone resorption [33].
Ovariectomized (OVX) animal models, in a variety of
species, have been used to evaluate the mechanism of or
to assess the effect of drugs in estrogen deficiency. The









Sham 81.6 ± 5.2* 7.7 ± 1.1 75.6 ± 4.2** 0.82 ± 0.11**
OVX 56.4 ± 6.3* 9.9 ± 2.2 101.3 ± 5.1 2.70 ± 1.10
CSIF-100 81.1 ± 11.2 7.6 ± 1.1 80.2 ± 18.2** 1.60 ± 0.02*
CSIF-50 66.6 ± 14.0 8.1 ± 3.2 95.1 ± 19.3* 1.96 ± 1.2*
CSIF-20 59.6 ± 14.2 8.9 ± 2.0 99.3 ± 14.1* 2.55 ± 0.02
Values are mean ± SEM. n = 10. *P <0.05 vs. OVX control; **P <0.01 vs.
OVX control.
Figure 2 Calcium solubility. CSIF-100 and CSIF-50 significantly decreased the amount of calcium released after 24 hours compared to OVX
animals, Values are mean ± SEM. n = 10. *p < 0.05, ** p < 0.01compared to the OVX group at the same timepoint.
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control rats (Table 1). The hypertrophy of the thymus
resulting from ovariectomy was inhibited by CSIF. The
results indicate CSIF could enhance the immune functions
in OVX animals.
Uterus is a primary target organ for estrogen. The
uterotrophic assay is a standard tool for determining the
estrogenic activity of a given substance in vivo [34]. This
study has shown for the first time that the oral administra-
tion of CSIF has significant estrogenic effects in OVX rats,
including dose-dependently increasing uterine weight,
restoring the uterine structure. In the current study, abso-
lute and relative uterine weight was significantly lower in
OVX rats than in Sham rats. Significant increase was
observed with CSIF in weight of atrophic uterus (Table 1).
These results may account for the possible mechanism of
the action of CSIF.
It has been reported that the serum biochemical parame-
ters, such as Ca and P are normal in osteoporosis in man
[35]. However, in the present investigation, significant dif-
ferences in Ca and P levels were found in different group.
CSIF treatments significantly decreased plasma total cal-
cium and inorganic phosphate concentrations. At the same
time, CSIF significantly decreased urinary Ca excretion. ItFigure 3 Representative images of the uterine sections. Representative
CSIF-100. (A) sham group, (B) OVX group, (C) CSIF-100 group. There was a
treatment. Sections were stained with H&E, Magnification X4.agrees with the above results of the increases in body
weight by CSIF and consistent with the finding that
body weight may contribute to maintaining the ele-
vated periosteal bone formation and inhibit endosteal
bone resorption [33].
It has been reported that phytoestrogens have the benefi-
cial effect of restoring the profile of such sex hormones as
E2, FSH and LH in women. FSH and LH are key stimula-
tors for follicular development. The preovulation secretion
of FSH and LH is negatively regulated by circulating E2 via
the feedback control system of the hypothalamic-pituitary-
ovarian axis [36].
In the current study, CSIF significantly increased serum
E2 levels and attenuated the elevated serum LH and FSH
levels resulting from the removal of E2 in OVX rats, in-
dicating that CSIF has a beneficial role in regulating
hypothalamic-pituitary function.
ALP is a non-collagenous protein secreted by osteo-
blast, which is essential for bone mineralization [37].
Increased ALP level in serum has been observed in
conditions such as rapid bone loss [38] and fracture
risk [39,40]. TRAPis secreted by osteoclasts during
bone resorption, and serum TRAP activity correlates with
resorptive activity in disorders of bone metabolism. In theimages of the uterine sections from OVX SD rats treated with
n obvious increase in the size of the lumen following CSIF-100
Figure 4 Histology of lumbar vertebrae. The bone structure was photographed under a light microscope. It shows that there was a significant
trabecular bone loss in the OVX rat (B), whereas the CSIF-100 treatment rat section (C) seems near normal compared with sham-operated
animals (A).
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TRAP levels commonly used bone remodeling markers. It
suggested that the potency of CSIF is due to decrease ALP
activity, TRAP activity in OVX rats.
Osteocalcin (OC) is known as serum markers reflecting
osteoblast activities including bone formation and turn-
over [41]. Treatment with CSIF increased OC level. The
result suggested that the treatment with CSIF induce the
secretion of OC after oral administration. Bone consists of
a calcified organic matrix, which is composed of 90% type
I collagen [42]. Higher C-terminal crosslinked telopeptides
of collagen type I (CTX) levels are associated with lower
bone mineral density values in osteoporosis [43]. The
serum levels of CTX were significantly lower in the CSIF
group than in the other groups. Substantial evidence dem-
onstrates that have shown that IFN-γ enhances osteoclast
generation in cultures of peripheral blood from osteope-
trotic patients [44]. Our study was consistent with this
finding. However, CSIF treated to the OVX rats decreased
significantly the IFN-γ level (P < 0.05).
These findings suggested that the effect of CSIF on
osteoporosis is due to decrease CTX and IFN-γ level, as
well as increase the OC level in plasma in OVX animals.
The mineral dissolution of bone from the CSIF treated
rats were reduced as compared with the control group
over the entire time period measured. The result assumed
that the decreased solubility of treated bone accounts in
part for its decreased resorbability. It is consistent with
the findings of above results. These findings suggested
that the potency of CSIF is due to dual effects on both
decreased resorption and increased formation. The histo-
logical examination clearly showed that dietary CSIF can
prevent bone loss caused by estrogen deficiency.
Conclusions
This study has shown for the first time that the oral
administration of CSIF has significant estrogenic effects
in OVX rats, including dose-dependently increasing
uterine weight, restoring the circulating E2, FSH, LH,ALP, TRAP, OC, CTX and IFN-γ levels, and preventing
bone loss due to E2 deficiency. The significant estrogenic
activity of CSIF demonstrated that CSIF has significant
estrogenic effects in OVX rats.
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